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Background. Data are limited on the determinants of homo-
cysteine (tHcy) and its relationship with nutritional indices, and
dietary protein intake, in the earlier stages of chronic kidney
disease (CKD).
Methods. Levels of tHcy were assayed at baseline (N = 804)
and 1 year postrandomization (N = 678) in the Modification
of Diet in Renal Disease (MDRD) Study [study A, glomeru-
lar filtration rate (GFR) 25 to 55 mL/min/1.73 m2 and study
B GFR 13 to 24 mL/min/1.73 m2]. Participants were randomly
assigned to different blood pressure targets and protein diets
and all subjects received a multivitamin supplement contain-
ing 1 mg of folic acid, 10 mg pyridoxal 5′-phosphate (PLP) and
6 lg of vitamin B12. Multivariable analyses were used to evalu-
ate determinants of tHcy at baseline and 1 year.
Results. The prevalence of hyperhomocysteinemia (tHcy >15
lmol/L) at baseline was 56% in study A and 85% in study B.
Baseline tHcy was negatively correlated with measures of body
fat and dietary protein intake. Folate, vitamin B12, and GFR
were the major determinants of tHcy levels. Of the patients
with hyperhomocysteinemia at baseline, 49% and 24% reduced
their tHcy levels at 1 year to ≤15 lmol/L in study A and study B,
respectively. There was no association between dietary protein
intake and odds of developing hyperhomocysteinemia at 1 year
in study A (P = 0.94) or study B (P = 0.10).
Conclusion. Hyperhomocysteinemia is partly amenable to
correction by vitamin supplementation in CKD stages 3 and 4.
There is insufficient evidence to suggest that low tHcy is asso-
ciated with poor nutritional status in the MDRD Study cohort.
B vitamins and GFR, but not dietary protein, are the major
determinants of tHcy in this patient population.
The prevalence of hyperhomocysteinemia is over 80%
among dialysis patients [1]. Proposed mechanisms for hy-
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perhomocysteinemia in kidney failure include deficien-
cies of folate, vitamin B12, and pyridoxal 5′-phosphate
(PLP), and reduced clearance of total plasma homocys-
teine (tHcy) secondary to defective kidney and/or extra
kidney metabolism of tHcy [2, 3]. The determinants of
hyperhomocysteinemia in patients in the earlier stages of
chronic kidney disease (CKD) has been less well studied
[4].
Hyperhomocysteinemia appears to be associated with
increased cardiovascular disease risk in the general pop-
ulation [5, 6]. Similarly, elevated levels of tHcy may be
associated with increased morbidity and mortality from
cardiovascular disease in patients with kidney failure [7–
9]. In contrast, low tHcy levels were associated with hos-
pitalization and mortality in hemodialysis patients [10–
12]. These studies also found a positive relationship be-
tween tHcy levels and serum albumin and protein intake.
Thus, an association between low tHcy levels and mal-
nutrition has been suggested as a possible explanation
for these paradoxic findings [10, 11]. However, there is
limited information concerning the relationship between
tHcy levels and nutritional markers in the earlier stages of
CKD.
Folate and vitamin B12 are the major determinants of
tHcy levels in the general population and in dialysis pa-
tients [13, 14]. Several clinical trials in dialysis patients
have found that folic acid and vitamin B12 supplemen-
tation, therapeutic measures that are highly effective in
the general population, do not normalize tHcy levels in
kidney failure; even when administered in supraphysio-
logic doses [15]. It is unknown if these strategies are more
effective if initiated earlier in CKD.
Dietary protein intake may also affect tHcy levels. Al-
though studies in the general population have noted an
inverse or no association between dietary protein and
methionine intake and tHcy levels [16, 17], in the dialy-
sis population there appears to be a positive relationship
between tHcy levels and both protein intake and mark-
ers of adequate or good nutritional status [18]. These
1539
1540 Menon et al: Determinants of homocysteine in chronic kidney disease
relationships have not been examined in patients with
CKD, prior to reaching kidney failure.
The Food and Drug Administration authorized the ad-
dition of folic acid to enriched grain products in March
1996, and made it mandatory in January 1998. The Mod-
ification of Diet in Renal Disease Study (MDRD Study)
was a randomized controlled clinical trial of dietary pro-
tein restriction and strict blood pressure control in pa-
tients with CKD stages 3 and 4, conducted from 1989 to
1993 and thus predating the folate fortification era. The
objectives of the analyses presented here were to assess
the prevalence and determinants of hyperhomocysteine-
mia at baseline, to examine the association between tHcy
and nutritional markers, and to study the effect of vita-
min supplementation and dietary protein intake on tHcy
levels at one year among MDRD Study participants.
METHODS
The Cleveland Clinic Foundation and Tufts-New
England Medical Center Institutional Review Boards ap-
proved all data collection procedures.
MDRD Study
The MDRD Study was a randomized controlled trial of
840 patients to study the effects of dietary protein restric-
tion and strict blood pressure control on the progression
of kidney disease [19]. Eligibility criteria for enrollment
into the MDRD Study included age 18 to 70 years, CKD
with serum creatinine 1.4 to 7.0 mg/dL (men) and 1.2 to
7.0 mg/dL (women). Patients with insulin-requiring dia-
betes, class III or IV congestive heart failure, renal artery
stenosis, and history of kidney transplantation or frequent
hospitalizations were excluded. Study A consisted of pa-
tients with a glomerular filtration rate (GFR) of 25 to
55 mL/min/1.73 m2 and study B of patients with a GFR
of 13 to 24 mL/min/1.73 m2. Etiologies of kidney diseases
were 25% polycystic kidney disease, 25% glomerular dis-
eases, and 50% other causes.
The interventions in the MDRD Study have been de-
scribed previously [20]. To summarize briefly, patients
were randomized to low (0.58 g/kg/day) protein versus
usual (1.3 g/kg/day) protein diet in study A. Patients in
study B were randomized to low (0.58 g/kg/day) versus
very low (0.28 g/kg/day) protein diet supplemented with
a mixture of ketoacids and amino acids. Patients in both
studies were also randomized to usual (≤107 mm Hg for
age ≤60 years, and ≤113 mm Hg for age >61 years) ver-
sus low (≤92 mm Hg for age ≤60 years, and ≤98 mm Hg
for age >61 years) blood pressure goals. At baseline, all
participants were prescribed a multivitamin supplement
containing 1 mg of folic acid, 10 mg PLP and 6 lg of
vitamin B12.
Daily protein intake at baseline was estimated from
3-day food records [20]. Adjusted protein intake was
estimated from urine urea nitrogen excretion at 1
year. Plasma levels of amino acids were analyzed at
baseline at the Central Amino Acid Laboratory, De-
partment of Pediatrics, University of Iowa, Iowa City,
Iowa.
Measurement of tHCY, folic acid, PLP, and vitamin B12
Serum samples from the MDRD Study cohort were
available from 804 (96% of randomized participants) pa-
tients at baseline (559 in study A and 245 in study B),
and 678 (81% of those randomized) patients at 1 year
follow-up (481 in study A and 197 in study B). As de-
scribed previously [21], after blood was drawn, samples
were allowed to clot at room temperature for a maxi-
mum of 2 hours prior to sample processing for serum
and placing on ice. Samples were shipped overnight to
the Central Biochemistry Laboratory at The Cleveland
Clinic Foundation, and stored at −70◦ C. Frozen samples
were then thawed, split and assayed for tHcy by high-
performance liquid chromatography (HPLC) with fluo-
rometric detection [22]. Serum PLP was assessed using
the tyrosine decarboxylase apoenzyme method. Serum
folate was measured by a microbial (Lactobacillus cas-
sei) assay, and serum vitamin B12 with a (Magic) radioim-
munoassay from Ciba-Corning. Details of assays used for
measurements of these analytes have been described pre-
viously [21].
Statistical analyses
Hyperhomocysteinemia was defined as fasting tHcy
>15 lmol/L; the upper limit of the normative range in
the prefortification era [23]. Descriptive statistics are re-
ported as percentages for categoric data, and mean and
standard deviation for normally distributed continuous
data. Skewed continuous variables were transformed to
natural logarithms and median and interquartile ranges
(IQR) are reported for these variables. Differences be-
tween groups were tested using the chi-square test,
Student t test, and the Mann-Whitney test as appropriate.
The strength of the association between tHcy and se-
lected nutritional markers was determined using Pear-
son’s correlations with natural log-transformed tHcy and
Spearman’s q correlation with nontransformed tHcy. The
results obtained from these analyses were similar and we
present results using nontransformed variables to facili-
tate interpretation of study findings. Multivariable regres-
sion procedures were used to evaluate the independent
determinants of tHcy at baseline and at 1 year follow-up.
For determinants of tHcy at baseline, a priori selected
variables included age, gender, race (white versus non-
white), cause of kidney disease (glomerular, polycystic
Menon et al: Determinants of homocysteine in chronic kidney disease 1541
Table 1. Baseline characteristics of the study population stratified by study and level of homocysteine (tHcy)
Study A Study B
tHcy ≤15 lmol/L tHcy >15 lmol/L tHcy ≤15 lmol/L tHcy >15 lmol/L
N = 249 N = 310 N = 38 N = 207
Age yearsa 52.8 ± 11.8 51.6 ± 12.3 48.4 ± 14.5 51.4 ± 12.6
Male% 51 68c 63 36d
White% 84 85 92 85
Current smoker% 8 12 21 6d
Etiology of kidney disease%
Glomerular 21 26 8 26d
Polycystic kidney disease 30 28 55 33
Other 49 46 37 41
History of diabetes% 5 5 11 4
History of coronary artery disease% 8 10 8 11
History of hypertension% 82 85 82 86
Glomerular filtration rate mL/min/1.73 m2a 41.4 ± 8.8 36.6 ± 8.4c 19.5 ± 3.2 18.4 ± 3.4
Creatinine mg/dLa 1.7 ± 0.4 2.1 ± 0.5c 3.1 ± 0.8 3.5 ± 0.9d
Total cholesterol mg/dLa 216.1 ± 45.5 220.5 ± 48.7 216.2 ± 39.1 212.6 ± 41.7
Proteinuria g/dayb 0.2 (0.9) 0.3 (1.3) 0.6 (2.3) 0.7 (1.9)
Albumin g/dLa 4.0 ± 0.3 4.1 ± 0.4c 3.8 ± 0.4 4.1 ± 0.4d
Vitamin B12 pg/mLb 461.5 (233.0) 379.8 (172.4)c 546.5 (290.6) 433.2 (212.1)d
Pyridoxal 5′-phosphate ng/mLb 42.4 (38.5) 34.8 (27.1)c 49.9 (68.1) 37.6 (37.0)d
Folate ng/mLb 12.0 (17.4) 7.1 (5.6)c 15.1 (29.9) 7.2 (6.4)d
tHcy lmol/Lb 12.5 (29) 18.7 (5.9)c 13.2 (2.2) 22.1 (8.4)d
aMean ± standard deviation.
bMedian (interquartile range).
cP < 0.05, patients with tHcy ≤15 lmol/L compared to those with tHcy >15 lmol/L in study A.
dP < 0.05, patients with tHcy ≤15 lmol/L compared to those with tHcy >15 lmol/L in study B.
kidney disease or other), smoking (current versus prior
or never), and baseline levels of albumin, daily protein
intake, GFR, folate, PLP, and vitamin B12. The regression
was repeated after inclusion of serum creatinine because
of the known direct association between serum creati-
nine, independent of GFR, with tHcy [24].
For determinants of tHcy at 1 year, the model included
the same set of a priori selected variables with the follow-
ing differences. One-year levels were used for albumin,
GFR, folate, PLP, and vitamin B12, and daily protein in-
take was replaced with randomization to the different
protein diets. The model also adjusted for randomiza-
tion to different blood pressure goals. The regression was
repeated using adjusted protein intake estimated from
urine urea nitrogen excretion at 1 year instead of ran-
domization assignment to protein diets. A mixed effects
model was used to test differences in selected factors at
baseline and 1 year.
The McNemar test was used to compare prevalence
of hyperhomocysteinemia at baseline and 1 year, strati-
fied by study. An analysis of variance (ANOVA) was per-
formed to relate percent change in the geometric mean
of tHcy from baseline to 1 year controlling for protein
diet and blood pressure assignments. The effect of differ-
ent protein diets on hyperhomocysteinemia was exam-
ined using a logistic regression procedure with protein
diet and blood pressure assignment, and baseline tHcy
as independent variables and hyperhomocysteinemia at
1 year as the dependent variable.
RESULTS
Baseline characteristics of study sample
Mean ± standard deviation and median (IQR) of tHcy
was 18.8 ± 9.7 lmol/L and 16.8 (8.0) lmol/L in the entire
cohort. Baseline characteristics, stratified by study and
level of tHcy, for all subjects with baseline values of tHcy
are presented in Table 1 (N = 804). The prevalence of
hyperhomocysteinemia at baseline was 56% in study A
and 85% in study B. More males in study A and females
in study B had hyperhomocysteinemia. Patients with hy-
perhomocysteinemia had higher levels of creatinine and
lower levels of vitamin B12, PLP, and folic acid in both
studies A and B, compared to patients with tHcy levels in
the normal range. There were no differences in age, race,
history of cardiovascular disease, diabetes, hypertension,
total cholesterol, and proteinuria between the high and
low tHcy groups in either study A or B. The high tHcy
group in study A had significantly lower levels of GFR. In
study B, there was a higher prevalence of glomerular dis-
ease and a lower prevalence of polycystic kidney disease
and smoking, among patients with hyperhomocysteine-
mia.
Univariate correlations of nutritional indices with
baseline tHcy levels
The associations between baseline tHcy and nutri-
tional markers were examined in univariate analyses
in the whole cohort (study A and study B combined).
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Table 2. Correlations between baseline homocysteine (tHcy) levels
and nutritional indices
Spearman correlation
coefficient
Folate ng/mL −0.47a
Vitamin B12 pg/mL −0.31a
Pyridoxal 5′-phosphate ng/mL −0.19a
Percent body fat% −0.20a
Body mass index kg/m2 −0.08a
Triceps skinfold thickness mm −0.17a
Daily protein intake g/kg/day −0.12a
Albumin g/dL 0.18a
Serum creatinine mg/dL 0.48a
aP < 0.05.
Table 3. Multivariable regression for independent determinants of
homocysteine (tHcy) levels at baseline
Change in tHcy levels
Change in predictor (95% confidence intervals) P value
Doubling of folate ng/mL ↓ 12% (11% to 13%) <0.001
Doubling of vitamin B12 ↓ 14% (12% to 17%) <0.001
pg/mL
10 mL/min/1.73 m2 increase ↓ 18% (17% to 19%) <0.001
in GFR
0.1 g/dL increase in albumin ↑ 2% (2% to 3%) <0.001
10 years increase in age ↑ 3% (2% to 4%) 0.01
Women versus men ↑ 10% (9% to 12%) <0.001
White race versus nonwhite ↑ 6% (3% to9%) 0.03
GFR is glomerular filtration rate. Natural log transformed values were used
for tHcy, vitamin B12, and folate; other variables in the model, that did not reach
statistical significance, included smoking status, etiology of kidney disease, and
pyridoxal 5′-phosphate.
Baseline tHcy was negatively correlated with baseline
values of folate, vitamin B12, PLP, percent body fat, body
mass index, triceps skinfold thickness, daily protein in-
take, and positively correlated with creatinine and albu-
min (Table 2). There was no association of baseline tHcy
with plasma levels of methionine.
Determinants of tHcy at baseline
Independent determinants of tHcy at baseline were
identified in multivariable regression analysis. Folate, vi-
tamin B12, and GFR were the primary determinants of
tHcy levels at baseline. Higher serum albumin level, older
age, female gender, and white race were also associated
with higher levels of tHcy (Table 3). Etiology of kidney
disease, smoking status, daily protein intake, and PLP did
not reach statistical significance. The regression was re-
peated after inclusion of serum creatinine. There was a
significant relationship between tHcy and creatinine (re-
gression coefficient ± standard error = 0.06 ± 0.02) (P =
0.02).
Analyses using 1-year follow-up tHcy levels
Frozen samples were available for measurement at
1-year follow-up in 678 participants. There was no differ-
Table 4. Multivariable regression for independent determinants of
homocysteine (tHcy) levels after 1 year of vitamin supplementation
Change in tHcy levels
Change in predictor (95% confidence intervals) P value
Doubling of folate ng/mL ↓ 7% (6% to 9%) <0.001
Doubling of vitamin B12 ↓ 10% (7% to 12%) <0.001
ng/mL
10 mL/min/1.73 m2 increase ↓ 10% (9% to 11%) <0.001
in GFR
0.1 g/dL increase in albumin ↑ 2% (1% to 2%) <0.001
10 years increase in age ↑ 5% (4% to 6%) <0.001
Women versus men ↑ 7% (5% to 9%) <0.01
White race versus nonwhite ↑ 7% (4% to 10%) 0.02
GFR is glomerular filtration rate. Natural log transformed values were used
for tHcy at 1 year, vitamin B12, and folate; other variables in the model, that
did not reach statistical significance, included smoking status, etiology of kidney
disease, pyridoxal 5′-phosphate, and randomization to different diets and blood
pressure goals.
ence in baseline level of tHcy (P = 0.43) and GFR (P =
0.09) between the 678 participants with follow-up tHcy
levels (median tHcy = 16.8 lmol/L, mean ± standard de-
viation GFR = 33 ± 12 mL/min/1.73 m2) and the 126
patients who did not have 1-year tHcy levels (tHcy =
16.9 lmol/L, GFR = 31 ± 13 mL/min/1.73 m2). There
were no differences between the groups with regard to
age, race, history of diabetes, or etiology of kidney dis-
ease; however, there were more men in the group with
missing follow up tHcy levels (data not shown). Mean ±
standard deviation and median (IQR) of tHcy at 1 year
was 15.3 ± 6.2 and 14.4 (6.1) lmol/L in the entire cohort.
Determinants of tHcy levels at 1 year
In multivariable analysis examining determinants of
tHcy at 1 year (Table 4), folate, vitamin B12, and
GFR remained important determinants in vitamin-
supplemented patients. Other determinants included al-
bumin, gender, race, and age. Randomization to different
protein diets was not an independent determinant of tHcy
at 1 year. The regression was repeated using estimated
protein intake at 1 year rather than randomization as-
signment to protein diet. Level of dietary protein intake
was not a significant predictor of tHcy levels at one year
(regression coefficient, 95% CI = −0.05, −0.13 to 0.03)
(P = 0.24).
In a mixed effects model comparing the effects of GFR,
folic acid, vitamins B12, B6, and albumin on tHcy levels at
baseline versus that at 1 year, there was no difference in
the regression coefficients for any of these factors except
folic acid which appeared to have less of an effect on tHcy
levels at 1 year (regression coefficient ± standard error
= −0.09 ± 0.02) (P < 0.01).
Effect of vitamin supplementation on tHcy levels at 1 year
The prevalence of hyperhomocysteinemia, defined as
tHcy >15 lmol/L, was compared at baseline and 1 year
in the 678 patients with frozen samples available at both
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time points. The prevalence of hyperhomocysteinemia
decreased significantly from baseline in both study A and
B (P < 0.001 for both comparisons). Of the patients with
hyperhomocysteinemia at baseline and with tHcy levels
available at 1 year (N = 434), 49% (130/268) reduced
their tHcy levels to the normal range in study A and 24%
(39/166) in study B. An additional 29/213 patients in study
A and 8/31 patients in study B, who had normal tHcy
levels at baseline, developed hyperhomocysteinemia at 1
year.
Effect of different protein diets on tHcy levels at 1 year
Baseline and 1-year levels of tHcy and known determi-
nants, stratified by study and dietary protein assignment,
are presented in Table 5. In an ANOVA procedure, per-
cent reductions of tHcy from baseline to 1 year were com-
pared between the different diet groups in each study,
controlling for blood pressure assignment. The percent
reduction in geometric mean of tHcy was similar between
the usual (17%) and low (17%) protein groups in study
A (P = 0.98). However, there was a trend in the very low
protein group in study B (21%) toward a larger percent
decrease in tHcy levels than the low protein (13%) group
(P = 0.05). In a logistic regression procedure accounting
for blood pressure assignment and baseline tHcy levels,
there was no significant association between randomiza-
tion assignment to low or usual protein diet and odds of
hyperhomocysteinemia at 1 year in either study A [odds
ratio (OR) 95% CI = 1.02, 0.66 to 1.55) (P = 0.94); how-
ever, in study B there was a trend toward lower odds
of hyperhomocysteinemia with the very low protein diet
compared to the low protein diet (OR 95% CI = 0.56,
0.28 to 1.12) (P = 0.10).
DISCUSSION
In the present study, with its large cohort of patients
with reduced kidney function, we found a high preva-
lence of hyperhomocysteinemia during the earlier stages
of kidney disease. Supplementation with 1 mg of folic
acid, 10 mg PLP, and 6 lg of vitamin B12 reduced tHcy
levels to within the normal range in half the participants
with moderate reductions in GFR (equivalent to CKD
stage 3) and a quarter of the participants with more severe
reductions in GFR (equivalent to CKD stage 4). Level of
protein in the diet did not appear to have a major effect
on tHcy levels.
Prevalence and determinants of tHcy levels at baseline
In the MDRD Study population, over half the patients
in study A and more than three fourths of the patients
in study B had hyperhomocysteinemia at baseline. This
is consistent with a reported prevalence of close to 90%
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among dialysis patients and those with advanced kidney
disease prior to initiation of dialysis [11, 25, 26].
Consistent with studies in the general population and
in dialysis patients, in the MDRD Study levels of folate,
vitamin B12, and GFR showed the strongest association
with baseline tHcy levels [1, 13, 14, 27–29]. Other deter-
minants included albumin, age, gender, and race. It has
been suggested that low tHcy levels may be a marker
for poor nutritional status and decreased protein intake
in patients with kidney failure, and that the relationship
between tHcy and cardiovascular disease outcomes may
be confounded by these associations [10–12, 30]. In the
MDRD Study cohort of patients with CKD stages 3 to
4, tHcy levels were inversely related to body mass index,
percent body fat, triceps and biceps skinfold thickness,
and protein intake. However, as in dialysis patients [10,
11], tHcy was positively related to serum albumin and
creatinine in our sample. Although the positive associa-
tion of albumin and creatinine with tHcy may be due to a
nutritional relationship, it may also be due to the fact that
tHcy is bound to albumin [31], and the metabolic path-
ways for synthesis of creatinine and tHcy are interrelated.
That is, the formation of adenosyl-homocysteine from
S-adenosyl methionine is coupled with creatinine synthe-
sis [24]. In sum, these data suggest that in this group of
relatively healthy patients in the earlier stages of CKD,
there is insufficient evidence that low tHcy levels are a
marker of poor nutritional status, as they may be in pa-
tients with kidney failure.
Determinants of tHcy levels at 1 year
In our study population, after 1 year of vitamin sup-
plementation, the effect of folic acid levels diminished
while GFR remained a major determinant of tHcy lev-
els. These findings are consistent with the experience
of patients with stable coronary artery disease in which
following fortification of cereal grain flour products
with folic acid, serum creatinine, and vitamin B12 sup-
planted folate as the major determinants of tHcy levels
[32].
Effect of vitamin supplementation on tHcy levels at 1 year
In the MDRD Study, repletion with 1 mg of folic acid
reduced tHcy levels significantly in both study A and
study B. Despite significant reductions in tHcy levels in
both groups, more patients in study A normalized their
tHcy levels compared to study B. The latter may be due to
higher baseline levels of tHcy in study B, but is also con-
sistent with studies examining the effect of folate and B
vitamin supplementation in patients with kidney failure
which demonstrate that while many patients responded
to therapy, tHcy levels in some were refractory to even
high doses of folate [25, 33, 34]. It is also consistent with
two other studies in patients with advanced kidney dis-
ease prior to initiation of dialysis [12, 25, 26]. Our data
suggest that vitamin supplementation reduces levels of
tHcy in some but not all patients with moderate and se-
vere reductions in GFR. We acknowledge however, that
the vitamin doses used in the MDRD Study were sig-
nificantly lower than those used in some studies of pa-
tients with kidney failure [15], and that had larger doses
been used, further reductions in tHcy may have been
achieved. We also cannot rule out that other unknown
factors were partially responsible for the reduction
in tHcy.
Effect of different protein diets on tHcy levels
Dietary protein intake can modulate tHcy levels in dif-
ferent ways. First, 25% of circulating tHcy is free and un-
bound to protein and it is this form of homocysteine that
is filtered by the glomerulus and available to metabolic
pathways within the kidney [31]. Data from a study by
Guttormsen et al [35] suggested that a protein-rich meal
acutely increased levels of free tHcy, with slower in-
creases in total tHcy thus altering the ratio of free to
bound tHcy [35]. Thus elevation in free tHcy with di-
etary protein can result in increased plasma clearance
secondary to increased filtration and uptake into the kid-
ney as well as at extra renal sites [3]. Second, methionine is
the principal dietary source of tHcy; therefore, increased
intake of methionine secondary to increased dietary pro-
tein may result in elevated tHcy levels.
Several studies have investigated the role of the first
pathway (i.e., increased protein intake leading to in-
creased catabolism of tHcy) in the general population.
One study found a negative correlation between dietary
protein intake and tHcy levels in an elderly population
[16]. Conversely a study of healthy men did not note any
effect of varying dietary methionine intake on tHcy lev-
els [36]. Similarly, data from the Atherosclerosis Risk in
Communities Study and a randomized controlled trial in
overweight subjects did not note any association between
high methionine or high protein diet and tHcy levels [17,
37]. In the dialysis population, the second pathway (i.e.,
increased dietary protein and methionine intake leading
to increased Hcy levels) may be more important due to
the absence of glomerular filtration. In support of this
hypothesis, two studies in the dialysis population showed
a positive correlation between tHcy levels and the nor-
malized protein equivalent of total nitrogen appearance,
a measure of dietary protein intake [10, 11].
In the MDRD Study, in univariate analysis, there was
a significant negative correlation between baseline tHcy
and dietary protein intake, but this relationship did not
persist in multivariate analysis. In addition, there was no
statistically significant association between protein diet
and tHcy, although we acknowledge that we may have
had limited power to detect relationships in study B.
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Study strengths and limitations
There were several limitations to our study. Changes in
level of tHcy was not a primary outcome of the dietary in-
tervention in the MDRD Study; therefore, as mentioned
above, we may be underpowered to detect significant re-
lationships. We measured total tHcy levels; thus, it is pos-
sible that we have missed a differential effect of level of
dietary protein on the ratio of free versus bound tHcy.
As described in a previous publication [21], a 2-hour
delay in sample processing may in theory result in a sys-
tematic measurement error resulting in elevated tHcy lev-
els due to release of tHcy from red blood cells. However,
studies specifically assessing changes at 2 hours found
relatively small increases in tHcy levels [38, 39]. Further-
more, as detailed in our discussion, the range of tHcy
levels, prevalence of hyperhomocysteinemia, and magni-
tude of associations with known variables such as folic
acid and GFR in our sample are very similar to those re-
ported in the literature. We acknowledge, however, that
measurement errors if they exist may lead to an underes-
timation of the relationships examined in this study.
The results of this study are generalizable to a relatively
healthy, nondiabetic predominantly white CKD popu-
lation. The strengths include a large, well-characterized
cohort with a wide range of kidney function. The low
prevalence of comorbid conditions reduces the poten-
tial for confounding. Furthermore, the use of randomized
groups and intent-to-treat analysis to evaluate the effect
of protein diet on tHcy also reduces potential bias.
CONCLUSION
There is a high prevalence of hyperhomocysteinemia
in patients with CKD, which is partly amenable to correc-
tion by relatively low doses of vitamin supplementation.
Kidney function is a major determinant of tHcy levels in
vitamin-deficient and vitamin-repleted patients. There is
insufficient evidence that low tHcy is a marker of poor
nutritional status in the MDRD Study cohort and level
of dietary protein intake does not appear to have a major
effect on tHcy levels in this patient population.
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